Sapna Nagar1, Samreen Ahmed2, Claire Peeples3, Nichole Urban3, Judy Boura4, Bryan Thibodeau2, Jan Akervall5, George Wilson6, Graham Long3, Peter Czako3. 1. Department of Surgery Beaumont Health System, 3811 West 13 Mile Road, 104-RI, Royal Oak, MI 48073, USA. Electronic address: snagar29@gmail.com. 2. Beaumont BioBank, Beaumont Health System, Royal Oak, MI, USA. 3. Department of Surgery Beaumont Health System, 3811 West 13 Mile Road, 104-RI, Royal Oak, MI 48073, USA. 4. Department of Biostatistics, Beaumont Health System, Royal Oak, MI, USA. 5. Department of Surgery Beaumont Health System, 3811 West 13 Mile Road, 104-RI, Royal Oak, MI 48073, USA; Beaumont BioBank, Beaumont Health System, Royal Oak, MI, USA. 6. Beaumont BioBank, Beaumont Health System, Royal Oak, MI, USA; Department of Radiation Oncology, Beaumont Health System, Royal Oak, MI, USA.
Abstract
BACKGROUND: Fine-needle aspiration (FNA) aids in the diagnosis of thyroid nodules. The expression of previously implicated genes was examined to potentially discriminate between benign and malignant thyroid samples. METHODS: Patients included for study had cytology demonstrating follicular cells of undetermined significance, atypical cells of undetermined significance, follicular neoplasm, or suspicion of malignancy with one of the following postoperative diagnoses: follicular thyroid adenomas, follicular thyroid carcinomas, or follicular variant of papillary thyroid carcinomas (FV-PTCs). FNA and tumor expression of human telomerase reverse transcriptase (hTERT), high-mobility group A2 (HMGA2), and trefoil factor 3/3-galactoside-binding lectin (T/G ratio) were analyzed. RESULTS: T/G ratios were not significantly different in the malignant and benign groups. HMGA2 was overexpressed in carcinoma states; however, only FV-PTCs were significant (P = .006). Tumor hTERT expression was detected in 25% of follicular thyroid carcinomas, whereas 5% of FV-PTCs and 10% of follicular thyroid adenomas had expression. FNA aspirates showed similar results. CONCLUSIONS: Although HMGA2 and hTERT showed differential expression, they did not consistently differentiate benign from malignant. Further study based on global gene expression is needed to identify markers that could serve as a diagnostic tool.
BACKGROUND: Fine-needle aspiration (FNA) aids in the diagnosis of thyroid nodules. The expression of previously implicated genes was examined to potentially discriminate between benign and malignant thyroid samples. METHODS:Patients included for study had cytology demonstrating follicular cells of undetermined significance, atypical cells of undetermined significance, follicular neoplasm, or suspicion of malignancy with one of the following postoperative diagnoses: follicular thyroid adenomas, follicular thyroid carcinomas, or follicular variant of papillary thyroid carcinomas (FV-PTCs). FNA and tumor expression of humantelomerase reverse transcriptase (hTERT), high-mobility group A2 (HMGA2), and trefoil factor 3/3-galactoside-binding lectin (T/G ratio) were analyzed. RESULTS: T/G ratios were not significantly different in the malignant and benign groups. HMGA2 was overexpressed in carcinoma states; however, only FV-PTCs were significant (P = .006). TumorhTERT expression was detected in 25% of follicular thyroid carcinomas, whereas 5% of FV-PTCs and 10% of follicular thyroid adenomas had expression. FNA aspirates showed similar results. CONCLUSIONS: Although HMGA2 and hTERT showed differential expression, they did not consistently differentiate benign from malignant. Further study based on global gene expression is needed to identify markers that could serve as a diagnostic tool.
Authors: Wenberger Lanza Daniel de Figueiredo; Eraldo Ferreira Lopes; Deborah Laredo Jezini; Lorena Naciff Marçal; Enedina Nogueira de Assunção; Paulo Rodrigo Ribeiro Rodrigues; Adolfo José da Mota; Diego Monteiro de Carvalho; Spartaco Astolfi Filho; João Bosco Lopes Botelho Journal: PLoS One Date: 2022-05-20 Impact factor: 3.752
Authors: Wiktor Paskal; Adriana M Paskal; Tomasz Dębski; Maciej Gryziak; Janusz Jaworowski Journal: Pathol Oncol Res Date: 2018-05-05 Impact factor: 3.201